Valute / CLDX
CLDX: Celldex Therapeutics Inc
22.08
USD
0.30
(1.34%)
Il tasso di cambio CLDX ha avuto una variazione del -1.34% per oggi. Durante la giornata, lo strumento è stato scambiato ad un minimo di 21.71 e ad un massimo di 23.02.
Segui le dinamiche di Celldex Therapeutics Inc. Le quotazioni in tempo reale aiutano a reagire velocemente alle variazioni di mercato. Scorrendo tra i diversi timeframe, è possibile monitorare le tendenze e le dinamiche dei tassi di cambio di minuti, ore, giorni, settimane e mesi. Utilizza queste informazioni per prevedere i cambiamenti del mercato e prendere decisioni di trading consapevoli.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
CLDX News
- Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX)
- Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics (NASDAQ:CLDX)
- La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics (NASDAQ:CLDX), Alcon (NYSE:ALC)
- Stifel reiterates Buy rating on Celldex stock despite EoE setback
- H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock
- Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech (NASDAQ:ADD), Aspen Insurance Hldgs (NYSE:AHL)
- Celldex stock price target lowered to $62 at Canaccord on EoE program halt
- Celldex stock price target lowered to $42 by H.C. Wainwright
- Celldex stock falls as Wells Fargo cuts price target on EOE trial failure
- Celldex’s mast cell therapy fails to improve eosinophilic esophagitis
- Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
- Celldex Therapeutics earnings beat by $0.01, revenue fell short of estimates
- scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
- Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback
- Celldex stock price target maintained at $50 by H.C. Wainwright
- Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
- Crude Oil Rises 6%; US Consumer Sentiment Surges In June - Senmiao Tech (NASDAQ:AIHS), Chanson International (NASDAQ:CHSN)
- Celldex shares jump on impressive skin disorder drug data
- Visa, Mastercard lead Friday’s market cap stock movers
- Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Bunge Global (NYSE:BG), AleAnna (NASDAQ:ANNA)
- Celldex stock maintains Overweight rating on promising CSU therapy results
- Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
- Celldex stock rating reiterated at Buy by Canaccord ahead of data release
- Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Intervallo Giornaliero
21.71
23.02
Intervallo Annuale
14.40
46.90
- Chiusura Precedente
- 22.38
- Apertura
- 22.52
- Bid
- 22.08
- Ask
- 22.38
- Minimo
- 21.71
- Massimo
- 23.02
- Volume
- 2.143 K
- Variazione giornaliera
- -1.34%
- Variazione Mensile
- 1.24%
- Variazione Semestrale
- 3.81%
- Variazione Annuale
- -45.82%
30 agosto, sabato